Yesterday (27th), the second anniversary work conference of the Yangtze River Delta Pharmaceutical Innovation and Development Alliance and the 2023 Yangtze River Delta First Biomedical Industry Chain Key Technology Seminar and Supply and Demand Docking Conference were successfully held in Shanghai. Nearly 100 experts, scholars and entrepreneurs in the domestic biomedical industry in the fields of government, industry, academia, research, medicine, finance and services discussed the new trend of industrial ecology and the new future of industry development around the policy innovation, technological innovation, talent training and internationalization of the biomedical industry.
As a leader in the Yangtze River Delta, Shanghai has continuously consolidated the R&D foundation of the biomedical industry and accelerated the construction of a world-class biomedical industry cluster. Especially since the beginning of this year, Shanghai has taken the lead in releasing action plans and action plans for synthetic biology, genetics, medical robots, and biomedical intelligent manufacturing space, adding 4 new domestic Class 1 innovative drugs, the third in the country, and 9 new Class 3 innovative medical devices, ranking second in the country. Since its establishment two years ago, the Yangtze River Delta Pharmaceutical Innovation and Development Alliance has been based in Shanghai and facing the Yangtze River Delta, actively carrying out industry research, subject research and ecological cooperation, contributing wisdom and strength to the high-quality development of the biomedical industry in Shanghai and the Yangtze River Delta, and achieving fruitful results. The alliance will continue to play the role of a platform rooted in the industry, serving the industry and cohesion, building an influential professional industry organization, promoting the integration and agglomeration of biomedical industry development resources, and boosting the biomedical industry in the Yangtze River Delta and even the whole country to a new height and write a new chapter.
The 2023 ** Working Economy Conference emphasized that it is necessary to promote industrial innovation with scientific and technological innovation, especially to promote new industries, new models and new kinetic energy with disruptive technologies and cutting-edge technologies, and develop new quality productivity. Biomedicine is a strategic emerging industry, an industry with high-quality development, an industry related to the national economy and people's livelihood, and one of the fields with the most likely disruptive innovation. In accordance with the spirit of the first economic work conference, we should fully understand the significance of strategic emerging industries in the biomedical industry and the significance of encouraging innovation to drive industrial development. Since 2015, China has implemented a series of policy measures, such as the reform of the drug review and approval system, cracking down on the falsification of clinical trial data, improving drug review standards, simplifying the drug approval process, improving the efficiency of drug review, and promoting the consistency evaluation of the quality and efficacy of generic drugs, which have promoted the leapfrog development of China's biomedical industry. However, China's biomedicine still faces challenges such as weak source innovation ability, sluggish capital market, and financing difficulties for enterprises, especially the dual obstacles of medical insurance access and hospital access for innovative drugs to enter clinical use. Therefore, the industry should work in the same direction and form a joint force to provide whole-chain support for biomedical innovation and development in R&D, access, production, use, and payment, and strive to create an institutional environment that encourages biomedical innovation.
The Yangtze River Delta accounts for about 30% of the country's biomedical output value, and the innovative drugs approved for marketing since 2016 account for about 60% of the country's total. In December 2021, the Yangtze River Delta Pharmaceutical Innovation and Development Alliance was initiated and established by six units, including the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai Yangtze River Delta Business Innovation Research Institute, Dian Diagnostics, Hengrui Pharmaceutical, Innovent Biologics, and Tianhui Capital, and now has 38 member units. The Shanghai Yangtze River Delta Pharmaceutical Innovation and Development Research Center, the executive body of the alliance, was also approved to be registered and established by the Shanghai Civil Affairs Bureau in June 2023, and the business supervisory unit is the Shanghai Municipal Commission of Economy and Information Technology.
Since its establishment, the alliance and the pharmaceutical innovation center have taken industry research, subject research and special seminars as the main starting points, actively promoted the policy innovation, technological innovation, talent training and internationalization of the pharmaceutical industry in the Yangtze River Delta region, and are committed to becoming "a good helper for work, a good partner for enterprise development, and a promoter of industrial innovation and people's health". Since the beginning of this year, the alliance and the Pharmaceutical Innovation Center have actively carried out research and research on the innovation and transformation of pharmaceutical source innovation, the acceleration of the admission of innovative drugs, the construction of regional ethical integration, the reform of medical services, and the tax policy of the biomedical industry, and have successively submitted policy recommendation reports to the competent departments of the industry.
This conference focused on the research results of related topics, and carried out professional and enthusiastic discussions and exchanges. At the same time, the 2023 Yangtze River Delta First Biomedical Industry Chain Key Technology Seminar and Supply and Demand Docking Conference were also held, using theme reports, special sharing, strategic cooperation signing, roundtable forums and other forms to discuss the difficult points of key technology breakthroughs in China's biomedical industry chain, effectively promote the joint innovation of upstream and downstream enterprises in the chain, enhance the resilience of the biomedical industry chain, and form a more innovative and higher value-added biomedical industry chain in open cooperation.
Author: Zhou Chen.
Text: Zhou Chentu: Photo provided by the interviewee Editor: Wang Wanyi Responsible editor: Zhu Yue.
*Please indicate the source of this article.